Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started?
Eli Lilly's key catalyst for 2027 could positively affect price action sooner than you think.
Overview
Compared to the overall stock market, Eli Lilly (NYSE: LLY) has delivered some fairly ho-hum year-to-date returns, rising just 7% since January. Yet there's a reason why it remains one of the most widely followed pharmaceutical stocks.
Eli Lilly continues to benefit greatly from the launch of its GLP-1 weight loss drugs. And on the horizon, a crop of new catalysts related to the stock's existing catalyst could get it firing on all cylinders once again.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.